Dimensional Fund Advisors
ENGN icon

Dimensional Fund Advisors’s enGene Therapeutics ENGN Stock Holding History

Dimensional Fund Advisors’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.2K Buy
38,291
+1,418
+4% +$5.78K ﹤0.01% 3175
2026
Q1 		$251K Buy
+36,873
New +$328K ﹤0.01% 3038

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Dimensional Fund Advisors's ENGN Position: Q2 2026 in Review

Dimensional Fund Advisors increased its enGene Therapeutics (ENGN) stake by 3.8% in Q2 2026, buying an estimated $5.78K and bringing the position to 38,291 shares worth $66.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3175.

Dimensional Fund Advisors first reported a position in ENGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $251K in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Dimensional Fund Advisors held 38,291 shares of enGene Therapeutics worth $66.2K as of Q2 2026.
  • Dimensional Fund Advisors bought 1,418 enGene Therapeutics shares in Q2 2026, an estimated $5.78K.
  • enGene Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #3175 holding.
  • Dimensional Fund Advisors first reported a position in enGene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Dimensional Fund Advisors's enGene Therapeutics position peaked at $251K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.